Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 18, 2023
Trader Robot's Precision: BNGO Profits +2.90% in 7 Days

Trader Robot's Precision: BNGO Profits +2.90% in 7 Days

In this article, we will examine the performance of the AI trading robots accessible through "Swing trader: Top High-Volatility Stocks v.2 (TA)" and their recent success with BNGO, a high-volatility stock. While the bots generated a notable gain of +2.90% over the previous week, a closer look at BNGO's latest earnings report may signal a potential price pull-back in the near future.

AI Trading Bots Generate Impressive Gains with BNGO:

The AI trading robots accessible at "Swing trader: Top High-Volatility Stocks v.2 (TA)" showcased their capabilities by achieving a remarkable +2.90% gain while trading BNGO over the course of the previous week. This substantial return highlights the effectiveness of AI-driven strategies in capitalizing on the volatile movements of high-risk stocks.

Expectations of a Price Pull-Back:

Despite the recent gains, it's crucial for investors to exercise caution. Technical analysis suggests that a price pull-back in BNGO's value may be on the horizon. A price pull-back refers to a temporary decline in the stock's price after a notable rally, which could offer an opportunity for potential buyers to enter the market at a more favorable price point.

Analyzing BNGO's Earnings Report:

One of the key factors that might contribute to a potential price pull-back is BNGO's recent earnings report. On May 09, the company reported earnings per share of -10 cents, which fell short of the market estimate of -10 cents. This missed estimate could lead to a decrease in investor confidence and a subsequent dip in the stock's price.

Market Capitalization and Shares Outstanding:

As of the latest available data, BNGO has 6.25 million shares outstanding, resulting in a current market capitalization of 198.80 million dollars. Market capitalization reflects the total market value of a company's outstanding shares and can be a useful indicator of the company's size and overall market perception.

Conclusion:

The AI trading robots accessible through "Swing trader: Top High-Volatility Stocks v.2 (TA)" demonstrated their prowess by generating a significant +2.90% gain with BNGO during the previous week. However, investors should approach this success with caution, as technical analysis indicates the possibility of a price pull-back in the near future. The recent earnings report, where BNGO missed market estimates, may contribute to a potential decline in the stock's value

Related Ticker: BNGO

Contributor

Dem Sem's AvatarDem Sem|Expert

BNGO in downward trend: price may decline as a result of having broken its higher Bollinger Band on September 02, 2026

BNGO broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 28 similar instances where the stock broke above the upper band. In 28 of the 28 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 43 cases where BNGO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for BNGO turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 11, 2026. You may want to consider a long position or call options on BNGO as a result. In 68 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

BNGO moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BNGO crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.

Following a +3.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 163 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 40 of 67 cases where BNGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.455) is normal, around the industry mean (4.967). P/E Ratio (0.002) is within average values for comparable stocks, (142.488). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.236). Dividend Yield (0.000) settles around the average of (0.015) among similar stocks. P/S Ratio (0.386) is also within normal values, averaging (74.760).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.43B. The market cap for tickers in the group ranges from 126 to 130.41B. ISRG holds the highest valuation in this group at 130.41B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -4%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 13%. NEPH experienced the highest price growth at 10%, while COO experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 60
Price Growth Rating: 54
SMR Rating: 81
Profit Risk Rating: 95
Seasonality Score: -50 (-100 ... +100)
View a ticker or compare two or three
BNGO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of technologies for analysis of large biological molecules

Industry PharmaceuticalsOther

Profile
Details
Industry
Biotechnology
Address
9540 Towne Centre Drive
Phone
+1 858 888-7600
Employees
97
Web
https://www.bionano.com
Interact to see
Advertisement
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.
NBIS shares surged approximately +10% in premarket trading on March 11, 2026, from a prior close of $96.32. The primary catalyst is the imminent addition of Nebius Group to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, March 12, 2026.
ORCL shares surged approximately +10.49% in Wednesday's premarket session, trading around $165.07 versus Tuesday's closing price of $149.40. The primary catalyst is Oracle's Q3 FY2026 earnings beat, with adjusted EPS of $1.79 vs. the $1.70 consensus estimate, and revenue of $17.2 billion topping the $16.92 billion forecast.
Shares of AngloGold Ashanti plc (AU) are down approximately 5.00% in early trading on March 11, 2026, falling from a prior close of $108.26 to around $102.85. The primary driver is a renewed pullback in gold prices, which has weighed heavily on gold mining equities across the board.
HMY shares are trading down approximately 13% in early session trading on March 11, 2026, following the release of the company's H1 FY26 interim results. Revenue of R44.4 billion (~US$2.6 billion) missed analyst consensus estimates of R47.56 billion, a significant shortfall that spooked investors.
FICO fell over 9% today, extending a multi‑week downtrend that has already knocked the stock more than 7% lower since its last earnings update. The decline comes despite strong recent financial results, including double‑digit revenue growth, expanding margins, and repeated earnings beats.
RERE fell roughly 10% today, giving back a portion of its strong gains over the past year and month, as traders reacted to fresh earnings and guidance. The company delivered robust Q4 2025 results, with revenue growth near 30% year over year and earnings per share ahead of consensus estimates, underscoring continued operational momentum.
Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5. New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.